Home›Trial›NCT06283667
NCT06283667ENROLLING BY INVITATION

Special Use - Results Surveillance on Long-term Use With Wegovy®

Study Summary

The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor. The study will last for about 4 years. Participant will be in the study for about 2 years (104 weeks).

Conditions
Obesity
Interventions / Drugs
Semaglutide
View on ClinicalTrials.gov ↗
Sponsor
NVO
Novo Nordisk
Diabetes/Obesity
F12/100
Study Details
Enrollment1000 participants
Primary Completion—
Lead SponsorNovo Nordisk A/S
Data Retrieved2026-04-11 02:55:47.366907+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 1,000 participants
Sponsor Catalyst Profile

Novo Nordisk (NVO) is the sponsoring company for this trial. BiotechSign currently grades this company F (12/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NVO Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.